FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:1276-1277 March 22, 2007 Number 12 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article PubMed Citation

To the Editor: Hoffmann and colleagues (Dec. 21 issue)¹ report on the use of statins and the outcome of immunotherapy with bacille Calmette–Guérin (BCG) vaccine in 84 patients with superficial bladder cancer. The authors report that over a median follow-up period of 46 months, 19 patients who were using statins had an increased risk of "more aggressive" disease.

We analyzed outcomes in a cohort of 156 patients (median follow-up, 56 months) who received BCG; 39 used statins during the treatment, and 117 did not. We found no significant differences between the two groups in the incidence of tumor recurrence (59% . . . [Full Text of this Article]

Related Letters:

Use of Statins and Outcome of BCG Treatment for Bladder Cancer
Hoffmann P., Roumeguère T., Schulman C., van Velthoven R.
Extract | Full Text | PDF  
N Engl J Med 2006; 355:2705-2707, Dec 21, 2006. Correspondence

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.